United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total transaction of $835,380.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,166.50. The sale was disclosed in a filing with the SEC, which is available at this link.

United Therapeutics Stock Up 0.7 %

NASDAQ:UTHR opened at $236.93 on Friday. The firm has a market cap of $11.15 billion, a P/E ratio of 11.94 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54. The firm has a 50-day simple moving average of $231.20 and a two-hundred day simple moving average of $228.44.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. United Therapeutics’s revenue was up 25.1% compared to the same quarter last year. During the same period last year, the business earned $2.67 EPS. Analysts predict that United Therapeutics Co. will post 23.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on UTHR. HC Wainwright restated a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $213.00 to $215.00 in a report on Monday, February 12th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Wedbush restated an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, SVB Leerink started coverage on shares of United Therapeutics in a report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective for the company. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $292.67.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Blue Trust Inc. increased its stake in United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares in the last quarter. Formidable Asset Management LLC boosted its holdings in shares of United Therapeutics by 1.5% during the 3rd quarter. Formidable Asset Management LLC now owns 3,636 shares of the biotechnology company’s stock valued at $821,000 after acquiring an additional 53 shares during the last quarter. Alaska Permanent Fund Corp boosted its holdings in shares of United Therapeutics by 1.7% during the 3rd quarter. Alaska Permanent Fund Corp now owns 3,330 shares of the biotechnology company’s stock valued at $752,000 after acquiring an additional 57 shares during the last quarter. MBM Wealth Consultants LLC boosted its holdings in shares of United Therapeutics by 2.7% during the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after acquiring an additional 59 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of United Therapeutics by 1.6% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock valued at $856,000 after acquiring an additional 61 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.